| | | | |
CUSIP No. G75398 100 | | 13D | | Page 5 of 7 pages |
Item 1. | Security and Issuer. |
This statement on Schedule 13D (the “Schedule 13D”) relates to the ordinary shares, par value £0.0001 per share (the “Ordinary Shares”), of Revolve AI Limited, a private limited liability company registered under the laws of England and Wales with the registration number 14573691 (the “Issuer”), whose principal executive offices are located at 3rd Floor, 80 New Bond Street, London, WIS 1SB, United Kingdom.
Item 2. | Identity and Background |
The Schedule 13D is being filed by the following persons (each a “Reporting Person” and, collectively, the “Reporting Persons”):
Daniel Wagner;
John Wagner; and
DBLP Sea Cow Limited (“DBLP”).
Daniel Wagner and John Wagner are both citizens of the United Kingdom. DBLP is a company incorporated in the Seychelles. The address for the principal business office of each Reporting Person is 5 New Street Square, London EC4A 3BF, United Kingdom.
The principal occupation of Daniel Wagner is CEO and Executive Director of the Issuer, and John Wagner is a director of the Issuer. Legal title to the shares of DBLP are held solely by Daniel Wagner and beneficially held by John Wagner. Daniel Wagner and John Wagner each serves as a director on the board of director of DBLP and, therefore, may be deemed to share voting and investment power over the shares held by DBLP
During the last five years, none of the Reporting Persons (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 3. | Source and Amount of Funds or Other Consideration. |
The responses to Items 2, 4, 5 and 6 of this Schedule,13D are incorporated into this Item 3 by reference.
On August 15, 2024 (the “Closing Date”), the Issuer consummated the previously announced business combination pursuant to the Business Combination Agreement, dated as of December 17, 2021, as amended on November 10, 2022 and further amended and restated pursuant to the terms of an amendment and restatement deed dated June 16, 2023 (as amended or supplemented from time to time, the “Business Combination Agreement”), by and among the Issuer, Armada Acquisition Corp. I, a Delaware corporation (“Armada”), Rezolve Limited, a private limited company organized under the laws of England and Wales (“Rezolve Limited”), and Rezolve Merger Sub, Inc., a Delaware corporation (“Rezolve Merger Sub”). Upon consummation of the Business Combination, on August 15, 2024, (i) the Issuer effected a re-classification of its share capital whereby the Issuer’s series A shares were reclassified as ordinary shares of same class as existing ordinary shares on issue in the Issuer, with nominal value £0.0001 per share (the “Ordinary Shares”) such that immediately following each Reporting Person held his or its applicable pro rata portion of the aggregate stock consideration (to the extent that he, she or it does not already hold such pro rata portion after the Pre-Closing Demerger in accordance with the terms and conditions set forth in the Business Combination Agreement (such steps and any additional necessary steps being collectively referred to as the “Company Reorganization”), and (ii) the Company merged with and into Rezolve Merger Sub, with Armada surviving as a wholly owned subsidiary of the Issuer, with shareholders of Armada received Ordinary Shares in exchange for their existing common stock of Armada and Armada warrant holders having their warrants automatically exchanged by assumption by the Issuer of the obligations under such warrants. The consideration deemed paid by Armada for Rezolve in the business combination was valued at One Billion, Six Hundred Thousand Dollars ($1,600,000,000), paid in the form of the ordinary shares of Rezolve (as the surviving company) valued at $10.00 per share.
The foregoing description of the Business Combination Agreement does not purport to be complete and is qualified in its entirety by reference to the Business Combination Agreement, which is incorporated by reference as an exhibit hereto.
Item 4. | Purpose of Transaction |
The responses set forth in Item 2, 3, 5 and 6 hereof are incorporated by reference in their entirety.
Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, subject to the agreements described herein, the Reporting Persons, at any time, and from time to time, may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management of the Issuer or the Board of Directors with respect to the business and affairs of the Issuer and may from time to time consider pursuing or proposing such matters with advisors, the Issuer, or other persons.
Except as set forth in this Item 4 of this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions specified in clauses (a) through (j) of the instructions to Item 4 of this Schedule 13D.
Item 5. | Interest in Securities of the Issuer |
(a) – (b)
(a)—(b) The information relating to the beneficial ownership of Common Stock by each of the Reporting Persons set forth in Rows 7 through 13 of the cover pages hereto (including the footnotes thereto) is incorporated by reference.
(c) Except as set forth in this Schedule 13D, no Reporting Person, has effected any transaction in the Common Stock in the 60 days preceding the date hereof.
(d) The information in Item 2 is incorporated by reference into this Item 5(d).
(e) Not applicable.